The Extracellular-Regulated Protein Kinase 5 (ERK5) Enhances Metastatic Burden in Triple-Negative Breast Cancer through Focal Adhesion Protein Kinase (FAK)-Mediated Regulation of Cell Adhesion

Scientists revealed that ERK5 was critical for maintaining the invasive capability of TNBC cells through FAK activation, and reported that a high level of ERK5 is a predictive marker of metastatic breast cancer.
[Oncogene]
Xu, Q., Zhang, J., Telfer, B. A., Zhang, H., Ali, N., Chen, F., Risa, B., Pearson, A. J., Zhang, W., Finegan, K. G., Ucar, A., Giurisato, E., & Tournier, C. (2021). The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion. Oncogene, 1–13. https://doi.org/10.1038/s41388-021-01798-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

RIPK1 Is a Negative Mediator in Aquaporin 1-Driven Triple-Negative Breast Carcinoma Progression and Metastasis

The receptor-interacting protein kinase 1 (RIPK1) was identified by researchers to have negatively mediated Aquaporin-driven TNBC progression and metastasis, identifying it as a potential therapeutic target for TNBC.
[npj Breast Cancer]
Yin, Z., Chen, W., Yin, J., Sun, J., Xie, Q., Wu, M., Zeng, F., & Ren, H. (2021). RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis. Npj Breast Cancer, 7(1), 1–11. https://doi.org/10.1038/s41523-021-00261-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

FOXA1 and Adaptive Response Determinants to HER2 Targeted Therapy in TBCRC 036

Researchers examined HER2-positive cell line responses to inhibition with lapatinib to characterize transcriptional and epigenetic changes.
[npj Breast Cancer]
Angus, S. P., Stuhlmiller, T. J., Mehta, G., Bevill, S. M., Goulet, D. R., Olivares-Quintero, J. F., East, M. P., Tanioka, M., Zawistowski, J. S., Singh, D., Sciaky, N., Chen, X., He, X., Rashid, N. U., Chollet-Hinton, L., Fan, C., Soloway, M. G., Spears, P. A., Jefferys, S., … Johnson, G. L. (2021). FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer, 7(1), 1–15. https://doi.org/10.1038/s41523-021-00258-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes

Scientists silenced Syndecan-1 in TNBC cell lines using a 3D human umbilical vein endothelial cell co-culture system to study its role in angiogenesis.
[Cancers]
Nassar, E., Hassan, N., El-Ghonaimy, E. A., Hassan, H., Abdullah, M. S., Rottke, T. V., Kiesel, L., Greve, B., Ibrahim, S. A., & Götte, M. (2021). Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes. Cancers, 13(10), 2318. https://doi.org/10.3390/cancers13102318 Cite
Full Article
Bookmark

No account yet? Register

0
Share

IMV’s Lead Immunotherapy to Be Investigated in Breast Cancer

IMV, Inc. announced that its lead compound, maveropepimut-S will be investigated in patients with hormone receptor positive/HER2-negative breast cancer.
[IMV, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Dr. Connie Eaves Elected into the Prestigious Royal Society

Dr. Connie Eaves was recognized for her development of robust functional methods to quantify and characterize distinct types of primitive blood and mammary cell precursors- now considered gold standards.
[The University of British Columbia]
Press Release
Bookmark

No account yet? Register

0
Share

AKC Canine Health Foundation Marks Pet Cancer Awareness Month with over $850,000 in Newly Awarded Cancer Grants

The AKC Canine Health Foundation announced $850,000 invested in eleven newly awarded canine cancer research grants, including the continued investigation into tumor-permissive collagen signatures in canine mammary gland tumors.
[AKC Canine Health Foundation]
Press Release
Bookmark

No account yet? Register

0
Share

Bedaquiline, an FDA-Approved Drug, Inhibits Mitochondrial ATP Production and Metastasis In Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase

Scientists found that Bedaquiline had no effect on the growth of non-tumorigenic mammary epithelial cells or primary tumors in vivo.
[Cell Death & Differentiation]
Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F., & Lisanti, M. P. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death & Differentiation, 1–21. https://doi.org/10.1038/s41418-021-00788-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Disrupting Tumor Vasculature and Recruitment of aPDL1-Loaded Platelets Control Tumor Metastasis

The authors utilized the mouse mammary carcinoma cell line 4T1 to develop a strategy that guided an anti-programmed cell death-ligand 1 (aPDL1) antibody to accumulate in metastatic lesions to promote anti-tumor immune responses.
[Nature Communications]
Li, H., Wang, Z., Chen, Z., Ci, T., Chen, G., Wen, D., Li, R., Wang, J., Meng, H., Bryan Bell, R., Gu, Z., Dotti, G., & Gu, Z. (2021). Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. Nature Communications, 12(1), 2773. https://doi.org/10.1038/s41467-021-22674-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Distinct Roles of Tumor Associated Mutations in Collective Cell Migration

Researchers measured a multidimensional migration phenotype for genetically defined human breast epithelial cell lines that ranged in their in vivo behavior from non-tumorigenic to aggressively metastatic.
[Scientific Reports]
Lee, R. M., Vitolo, M. I., Losert, W., & Martin, S. S. (2021). Distinct roles of tumor associated mutations in collective cell migration. Scientific Reports, 11(1), 10291. https://doi.org/10.1038/s41598-021-89130-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Human Ribonuclease 1 Serves as a Secretory Ligand of Ephrin A4 Receptor and Induces Breast Tumor Initiation

Scientists used 4T1 mammary tumor cells to validate the contribution of the human ribonuclease 1–tyrosine kinase receptor ephrin A4 axis to breast tumorigenicity.
[Nature Communications]
Lee, H.-H., Wang, Y.-N., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Wang, Y.-H., Jiang, Z., Xu, S., Yao, J., Qiu, Y., Hsu, Y.-H., Hwang, W.-L., Yan, M., Cha, J.-H., Hsu, J. L., Shen, J., Ye, Y., Wu, X., … Hung, M.-C. (2021). Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications, 12(1), 2788. https://doi.org/10.1038/s41467-021-23075-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share